NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer

Cell

Volumn 170, Issue 6, 2017, Pages 1096-1108.e13

  Grinberg Bleyer, Yenkel ^a   Oh, Hyunju ^a   Desrichard, Alexis ^b   Bhatt, Dev M ^a   Caron, Rachel ^a   Chan, Timothy A ^b   Schmid, Roland M ^c   Klein, Ulf ^a,e   Hayden, Matthew S ^a,d   Ghosh, Sankar ^a  

^a Columbia University ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

cancer; immunotherapy; NF B; regulatory T cells

Indexed keywords

CD103 ANTIGEN; GAMMA INTERFERON; HERMES ANTIGEN; KI 67 ANTIGEN; TAMOXIFEN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MELANOGENESIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; RNA SEQUENCE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-REL; T-LYMPHOCYTES, REGULATORY;

EID: 85028909876     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.08.004     Document Type: Article

References (55)

1. Algul, H., Treiber, M., Lesina, M., Nakhai, H., Saur, D., Geisler, F., Pfeifer, A., Paxian, S., Schmid, R.M., Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J Clin Invest. 117 (2007), 1490–1501.
2. Baumgartner, J.M., Gonzalez, R., Lewis, K.D., Robinson, W.A., Richter, D.A., Palmer, B.E., Wilson, C.C., McCarter, M.D., Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J. Surg. Res. 154 (2009), 13–20.
3. Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S., Baltimore, D., Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376 (1995), 167–170.
4. Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.E., Schaeverbeke, T., Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med., 13, 2015, 211.
5. Boissonnas, A., Scholer-Dahirel, A., Simon-Blancal, V., Pace, L., Valet, F., Kissenpfennig, A., Sparwasser, T., Malissen, B., Fetler, L., Amigorena, S., Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 32 (2010), 266–278.
6. Bravo-Cuellar, A., Hernández-Flores, G., Lerma-Díaz, J.M., Domínguez-Rodríguez, J.R., Jave-Suárez, L.F., De Célis-Carrillo, R., Aguilar-Lemarroy, A., Gómez-Lomeli, P., Ortiz-Lazareno, P.C., Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65. J. Biomed. Sci., 20, 2013, 13.
7. Chen, S., Lee, L.F., Fisher, T.S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G.H., Tsaparikos, K., Li, X., et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol. Res. 3 (2015), 149–160.
8. Curran, M.A., Montalvo, W., Yagita, H., Allison, J.P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107 (2010), 4275–4280.
9. Darrasse-Jèze, G., Bergot, A.S., Durgeau, A., Billiard, F., Salomon, B.L., Cohen, J.L., Bellier, B., Podsypanina, K., Klatzmann, D., Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J. Clin. Invest. 119 (2009), 2648–2662.
10. De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R.J., Provasi, E., Sarnicola, M.L., Panzeri, I., et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45 (2016), 1135–1147.
11. Deree, J., Melbostad, H., Loomis, W.H., Putnam, J.G., Coimbra, R., The effects of a novel resuscitation strategy combining pentoxifylline and hypertonic saline on neutrophil MAPK signaling. Surgery 142 (2007), 276–283.
12. Dias, S., D'Amico, A., Cretney, E., Liao, Y., Tellier, J., Bruggeman, C., Almeida, F.F., Leahy, J., Belz, G.T., Smyth, G.K., et al. Effector regulatory T cell differentiation and immune homeostasis depend on the transcription factor Myb. Immunity 46 (2017), 78–91.
13. DiDonato, J.A., Mercurio, F., Karin, M., NF-κB and the link between inflammation and cancer. Immunol. Rev. 246 (2012), 379–400.
14. Donkor, M.K., Sarkar, A., Savage, P.A., Franklin, R.A., Johnson, L.K., Jungbluth, A.A., Allison, J.P., Li, M.O., T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 35 (2011), 123–134.
15. Dua, P., Ingle, A., Gude, R.P., Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma. Int. J. Cancer 121 (2007), 1600–1608.
16. Edward, M., MacKie, R.M., Pentoxifylline enhances lung colonization and alters cell adhesion and glycosaminoglycan synthesis by metastatic B16 melanoma cells. Int. J. Cancer 49 (1991), 711–716.
17. Fingert, H.J., Pu, A.T., Chen, Z.Y., Googe, P.B., Alley, M.C., Pardee, A.B., In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res. 48 (1988), 4375–4381.
18. Francisco, L.M., Sage, P.T., Sharpe, A.H., The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236 (2010), 219–242.
19. Greten, F.R., Arkan, M.C., Bollrath, J., Hsu, L.C., Goode, J., Miething, C., Göktuna, S.I., Neuenhahn, M., Fierer, J., Paxian, S., et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130 (2007), 918–931.
20. Godec, J., Tan, Y., Liberzon, A., Tamayo, P., Bhattacharya, S., Butte, A.J., Mesirov, J.P., Haining, W.N., Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation. Immunity 44 (2016), 194–206.
21. Heise, N., De Silva, N.S., Silva, K., Carette, A., Simonetti, G., Pasparakis, M., Klein, U., Germinal center B-cell maintenance and differentiation are controlled by distinct NF-kappaB transcription factor subunits. J Exp Med. 211 (2014), 2103–2118.
22. Huehn, J., Siegmund, K., Lehmann, J.C., Siewert, C., Haubold, U., Feuerer, M., Debes, G.F., Lauber, J., Frey, O., Przybylski, G.K., et al. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 199 (2004), 303–313.
23. Isomura, I., Palmer, S., Grumont, R.J., Bunting, K., Hoyne, G., Wilkinson, N., Banerjee, A., Proietto, A., Gugasyan, R., Wu, L., et al. c-Rel is required for the development of thymic Foxp3+ CD4 regulatory T cells. J. Exp. Med. 206 (2009), 3001–3014.
24. Jandus, C., Bioley, G., Speiser, D.E., Romero, P., Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol. Immunother. 57 (2008), 1795–1805.
25. Jimenez, J.L., Punzón, C., Navarro, J., Muñoz-Fernández, M.A., Fresno, M., Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 299 (2001), 753–759.
26. Kamran, M.Z., Gude, R.P., Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed. Pharmacother. 67 (2013), 399–405.
27. Kim, H.J., Hawke, N., Baldwin, A.S., NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 13 (2006), 738–747.
28. Kleffel, S., Posch, C., Barthel, S.R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C.P., Lee, N., Juneja, V.R., Zhan, Q., et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162 (2015), 1242–1256.
29. Köntgen, F., Grumont, R.J., Strasser, A., Metcalf, D., Li, R., Tarlinton, D., Gerondakis, S., Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9 (1995), 1965–1977.
30. Levine, A.G., Arvey, A., Jin, W., Rudensky, A.Y., Continuous requirement for the TCR in regulatory T cell function. Nat. Immunol. 15 (2014), 1070–1078.
31. Long, M., Park, S.G., Strickland, I., Hayden, M.S., Ghosh, S., Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 31 (2009), 921–931.
32. Luo, C.T., Liao, W., Dadi, S., Toure, A., Li, M.O., Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity. Nature 529 (2016), 532–536.
33. Messina, N., Fulford, T., O'Reilly, L., Loh, W.X., Motyer, J.M., Ellis, D., McLean, C., Naeem, H., Lin, A., Gugasyan, R., et al. The NF-κB transcription factor RelA is required for the tolerogenic function of Foxp3(+) regulatory T cells. J. Autoimmun. 70 (2016), 52–62.
34. Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30 (2009), 899–911.
35. Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W.J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109 (2007), 3177–3188.
36. Nakagawa, H., Sido, J.M., Reyes, E.E., Kiers, V., Cantor, H., Kim, H.J., Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. Proc. Natl. Acad. Sci. USA 113 (2016), 6248–6253.
37. Neo, W.H., Lim, J.F., Grumont, R., Gerondakis, S., Su, I.H., c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells. J. Biol. Chem. 289 (2014), 31693–31707.
38. Nishikawa, H., Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 127 (2010), 759–767.
39. Oeckinghaus, A., Hayden, M.S., Ghosh, S., Crosstalk in NF-κB signaling pathways. Nat. Immunol. 12 (2011), 695–708.
40. Oh, H., Grinberg-Bleyer, Y., Liao, W., Maloney, D., Wang, P., Wu, Z., Wang, J., Bhatt, D.M., Heise, N., Schmid, R.M., et al. An NF-κB transcription factor-dependent, lineage specific transcriptional program promotes regulatory T cell identity and function. Immunity, 47, 2017, 10.1016/j.immuni.2017.08.010.
41. Ouyang, W., Liao, W., Luo, C.T., Yin, N., Huse, M., Kim, M.V., Peng, M., Chan, P., Ma, Q., Mo, Y., et al. Novel Foxo1-dependent transcriptional programs control T(reg) cell function. Nature 491 (2012), 554–559.
42. Ouyang, Z., Wu, H., Li, L., Luo, Y., Li, X., Huang, G., Regulatory T cells in the immunotherapy of melanoma. Tumour Biol. 37 (2016), 77–85.
43. Pinzani, M., Marra, F., Caligiuri, A., DeFranco, R., Gentilini, A., Failli, P., Gentilini, P., Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br. J. Pharmacol. 119 (1996), 1117–1124.
44. Ratheesh, A., Ingle, A., Gude, R.P., Pentoxifylline modulates cell surface integrin expression and integrin mediated adhesion of B16F10 cells to extracellular matrix components. Cancer Biol. Ther. 6 (2007), 1743–1752.
45. Rosenblum, M.D., Gratz, I.K., Paw, J.S., Lee, K., Marshak-Rothstein, A., Abbas, A.K., Response to self antigen imprints regulatory memory in tissues. Nature 480 (2011), 538–542.
46. Ruan, Q., Kameswaran, V., Tone, Y., Li, L., Liou, H.C., Greene, M.I., Tone, M., Chen, Y.H., Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity 31 (2009), 932–940.
47. Samstein, R.M., Arvey, A., Josefowicz, S.Z., Peng, X., Reynolds, A., Sandstrom, R., Neph, S., Sabo, P., Kim, J.M., Liao, W., et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 151 (2012), 153–166.
48. Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
49. Shono, Y., Tuckett, A.Z., Ouk, S., Liou, H.C., Altan-Bonnet, G., Tsai, J.J., Oyler, J.E., Smith, O.M., West, M.L., Singer, N.V., et al. A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity. Cancer Discov. 4 (2014), 578–591.
50. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
51. Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. USA 110 (2013), 17945–17950.
52. Suresh, R., Vig, M., Bhatia, S., Goodspeed, E.P., John, B., Kandpal, U., Srivastava, S., George, A., Sen, R., Bal, V., et al. Pentoxifylline functions as an adjuvant in vivo to enhance T cell immune responses by inhibiting activation-induced death. J. Immunol. 169 (2002), 4262–4272.
53. Tang, Q., Bluestone, J.A., The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9 (2008), 239–244.
54. Vahl, J.C., Drees, C., Heger, K., Heink, S., Fischer, J.C., Nedjic, J., Ohkura, N., Morikawa, H., Poeck, H., Schallenberg, S., et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool. Immunity 41 (2014), 722–736.
55. Wang, W., Tam, W.F., Hughes, C.C., Rath, S., Sen, R., c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6 (1997), 165–174.